Evidence map›Paper›PMID 23523660›Full record

ArticlePulmonary pharmacology & therapeutics2014

Aminophylline infusion for status asthmaticus in the pediatric critical care unit setting is independently associated with increased length of stay and time for symptom improvement.

Abdallah R Dalabih, Steven A Bondi, Zena L Harris, Benjamin R Saville, Wenli Wang, Donald H Arnold

Abstract read
In one paragraph

Article in Pulmonary pharmacology & therapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Article
  7. Evaluation and treatment of critical asthma syndrome in children.Clinical reviews in allergy & immunology · 2015
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Abdallah R DalabihUniversity of Missouri School of Medicine, Department of Child Health, Division of Pediatric Critical Care, 404 Keene St, Columbia, MO 65201, USA. Electronic address: dalabiha@missouri.edu.
Steven A BondiVanderbilt University School of Medicine, Department of Pediatrics, Division of Pediatric Critical Care, USA. Electronic address: steven.a.bondi@vanderbilt.edu.
Zena L HarrisNorthwestern University Feinberg School of Medicine, Division of Pediatric Critical Care, USA. Electronic address: zena.harris@vanderbilt.edu.
Benjamin R SavilleVanderbilt University School of Medicine, Department of Biostatistics, USA. Electronic address: b.saville@vanderbilt.edu.
Wenli WangVanderbilt University School of Medicine, Department of Biostatistics, USA. Electronic address: steffi4444@gmail.com.
Donald H ArnoldVanderbilt University School of Medicine, Department of, Pediatrics, Division of Emergency Medicine, USA; Center for Asthma & Environmental Sciences Research, USA. Electronic address: don.arnold@vanderbilt.edu.
Vanderbilt University · USNorthwestern University · USUniversity of Missouri Health System · US

Funding

Development of a Pediatric Acute Asthma Prediction Rule for severity and outcomeK23HL080005 · NHLBI · VANDERBILT UNIVERSITY · PI ARNOLD, DONALD HAYES · 2008 to 2012
$738k
NHLBI NIH HHS K23 HL080005NHLBI NIH HHS K23 HL80005-01A2
6 · The paper itself

Abstract

introductionThe role of aminophylline in the treatment of severe acute asthma in the pediatric critical care unit (PCCU) is not clear. We sought to examine the association of aminophylline treatment with PCCU length of stay and time to symptom improvement. MATERIAL AND

methodsPatients with severe acute asthma who were admitted to our PCCU and received aminophylline infusion were retrospectively compared with similar patients who did not receive aminophylline. The primary outcome measure was functional length of stay (i.e. time to which patients could be transferred to a general pediatric ward bed). A secondary outcome was time to symptom improvement.

resultsAdjusted functional length of stay was longer for subjects who received aminophylline (n = 49) than for the patients who did not (n = 47) (hazard ratio 0.396, p < 0.001), as well as the time for symptom improvement (hazard ratio 0.359, p < 0.001). In the group of subjects receiving aminophylline, those with a serum theophylline level ≥ 10 mcg/ml (therapeutic) (n = 31) had longer functional length of stay (hazard ratio 0.457, p = 0.0225) and time to symptom improvement (hazard ratio 0.403, p = 0.0085) than those with levels < 10 mcg/ml (sub-therapeutic) (n = 18).

conclusionsThe addition of aminophylline to therapy with corticosteroids and inhaled β-agonists was associated with statistically and clinically significant increases in functional length of stay and time to symptom improvement in the PCCU. This potential morbidity supports the National Asthma Education and Prevention Program guideline proscribing aminophylline use in acute asthma.

Indexed as

Intensive Care Units, PediatricAdolescentAdrenergic beta-AgonistsAminophyllineBronchodilator AgentsChildChild, PreschoolDrug Therapy, CombinationFemaleGlucocorticoidsHumansInfusions, IntravenousLength of StayMaleRetrospective StudiesSeverity of Illness IndexAdrenergic beta-AgonistsAminophyllineBronchodilator AgentsGlucocorticoidsTheophyllineAminophyllineAsthmaelectronic medical recordEMRFLOSfunctional length of stayhazard ratioHRintravenousIVlength of stayLength of stayLOSmcg/mlmicrogram per millilitersnnumberPCCUPediatric critical carepediatric critical care unitRDSrespiratory distress score

Identifiers

PMID23523660
PMCPMC3732550
OpenAlexW2028329124

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.